Key Takeaways:
- Carthera’s SonoCloud-9 demonstrates safety and potential efficacy in treating recurrent glioblastoma.
- Phase III registrational trial underway to evaluate overall survival of patients undergoing carboplatin chemotherapy with SonoCloud-9.
- Clinical evidence published in Nature Communications suggests improved outcomes for patients with recurrent glioblastoma.
Unveiling Breakthrough Results: Carthera’s SonoCloud-9 Redefines Glioblastoma Treatment
Paris, France, March 4, 2024 – In a landmark development in the field of neurosurgery, Carthera, a spin-off from Sorbonne University, announces the publication of groundbreaking results in Nature Communications. The findings stem from the phase I/II clinical trial of the SonoCloud-9 device, marking a significant advancement in the treatment of recurrent glioblastoma (rGBM), a highly aggressive form of brain cancer.
The Clinical Trial: Assessing Safety and Efficacy
The phase I/II clinical trial assessed the safety and efficacy of Carthera’s SonoCloud-9 device in combination with carboplatin chemotherapy for patients with recurrent glioblastoma. Conducted across six clinical sites in France and the United States, the trial involved 33 patients receiving carboplatin after surgery, with activation to disrupt the blood-brain barrier (BBB) performed every four weeks using the SonoCloud-9 system.
Positive Results and Implications for Patient Care
The results demonstrated the safety profile of the SonoCloud-9 in opening the BBB for the delivery of drug therapies. Notably, patients who received carboplatin just before sonication exhibited a one-year overall survival rate of 58% and a median overall survival of 14 months from surgery. These outcomes surpass historical survival rates, suggesting that administering drugs prior to sonication with the SonoCloud-9 system may lead to improved clinical outcomes for patients with recurrent glioblastoma.
Professor Alexandre Carpentier, head of the neurosurgery department at AP-HP Sorbonne University and founder of Carthera, emphasizes the significance of the findings: “The publication of our clinical results in the highly respected Nature Communications journal demonstrates the significance of the SonoCloud technology as a viable new treatment option for patients with recurrent glioblastoma.”
Moving Towards Phase III: The SONOBIRD Trial
Building upon the success of the phase I/II trial, Carthera has initiated the SONOBIRD randomized phase III trial. This pivotal trial aims to validate the observed results and compare the efficacy of treating glioblastoma patients with the SonoCloud-9 in combination with carboplatin against standard care treatments. The trial seeks to establish the role of SonoCloud-9 in enhancing overall survival and quality of life for patients with recurrent glioblastoma.
About SonoCloud-9: Revolutionizing Brain Treatment
The SonoCloud-9 device, developed by Carthera, offers a revolutionary approach to treating brain disorders. Implanted below the skin, the device disrupts the BBB temporarily, allowing for the administration of drug therapies with higher efficacy. Carthera’s innovative technology holds the potential to transform the treatment landscape for patients with glioblastoma and other brain disorders, offering hope for improved outcomes and enhanced quality of life.
Conclusion: Pioneering Progress in Glioblastoma Treatment
Carthera’s groundbreaking research and development efforts underscore its commitment to advancing the field of neurosurgery. The publication of positive results in Nature Communications heralds a new era in the treatment of recurrent glioblastoma, offering hope and optimism for patients and healthcare professionals alike. As the SONOBIRD trial progresses, Carthera remains at the forefront of innovation, driving towards the realization of effective, life-saving therapies for those battling brain disorders.
Sign up to our newsletter & get the most important monthly insights from around the world.
Ready to Amplify Your Brand with Business Today?
Discover the power of sponsored articles and partnerships to reach decision-makers, professionals, and a dynamic audience. Learn more about our advertising opportunities and connect with us today!
Click here to explore our Promotion & Sponsored Articles page.
Are you looking to make an impact? Contact us at pitch@businesstoday.news to get started!
